In Reply to "Multiple-Biomarker Panel Estimated GFR Is Not Optimal or Cost-Effective" and "Comparing Multiple-Biomarker Panels for Estimating GFR With Estimating Equations Without a Coefficient Distinguishing Black Individuals From Persons of Other Groups"

Am J Kidney Dis. 2021 May;77(5):824. doi: 10.1053/j.ajkd.2021.01.007. Epub 2021 Feb 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers
  • Black or African American*
  • Cost-Benefit Analysis
  • Humans
  • Intramolecular Oxidoreductases
  • Lipocalins*

Substances

  • Biomarkers
  • Lipocalins
  • Intramolecular Oxidoreductases
  • prostaglandin R2 D-isomerase